Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma
Clinical Lymphoma Myeloma and Leukemia · 2024-04 · 24 (4) · 254-259
DOI: 10.1016/j.clml.2023.12.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-04. Verfasst von Alexandra Rezazadeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Mantle cell lymphoma (MCL) accounts for 4% to 6% of B-cell non-Hodgkin lymphoma with historically poor outcomes. With the advent of intensive first-line, targeted, and cellular therapies, outcomes have improved, and initial remission can be 8 to 10 years or longer. As patients experience longer remissions, this raises the question of the optimal surveillance modality. Peripheral blood minimal residual disease (MRD) analysis offers a potential alternative to surveillance imaging that is sensitive, less costly, and eliminates the risk of radiation exposure. MATERIALS AND METHODS: The clonoSEQ assay (Adaptive Biotechnologies) is an FDA-cleared commercially available Ig-HTS MRD assay with a sensitivity of 1 cell in 1,000,000. We performed a retrospective analysis of 34 patients from 2015 to 2021, who underwent MRD testing after achieving remission with first-line therapy. RESULTS: With a median follow-up of 6.5 years, 10-year progression free survival (PFS) was 60% and 10-year overall survival was 92% of the entire cohort. Among 12 patients who sustained a radiographic relapse, peripheral blood became MRD+ either at or prior to the time of relapse in 11 patients (92%). The first MRD+ test had a lead time of 0 to 24 months (median 34 days) prior to radiographic relapse. Only 1 patient had a MRD- result while being found to have progressive disease on imaging. Among 22 patients who sustained continuous clinical remission, 21 have remained MRD-. Several patients were able to enjoy 2 to 4-year intervals without surveillance imaging. CONCLUSIONS: Our data suggest that the clonoSEQ MRD assay is an effective surveillance tool for MCL patients following first-line therapy and is predictive of relapse prior to imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI.
- Providence Cancer Institute, Portland, OR.
- Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI; BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI.
- Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI; BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI. Electronic address: tfenske@mcw.edu.
Zitieren
APA
Rezazadeh, A., Pruett, J., Detzner, A., Edwin, N., Hamadani, M., Shah, N. N., & Fenske, T. S. (2024). Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 24(4), 254-259. https://doi.org/10.1016/j.clml.2023.12.006
Vancouver
Rezazadeh A, Pruett J, Detzner A, Edwin N, Hamadani M, Shah NN, et al. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2024;24(4):254-259. doi:10.1016/j.clml.2023.12.006
BibTeX
@article{Rezazadeh2024,
author = {Rezazadeh, Alexandra and Pruett, Julie and Detzner, Amy and Edwin, Natasha and Hamadani, Mehdi and Shah, Nirav N and Fenske, Timothy S},
title = {Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
volume = {24},
number = {4},
pages = {254--259},
doi = {10.1016/j.clml.2023.12.006}
}
EUVIMED